Clinical Trial Update: Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of magrolimab in combination with rituximab (with or without chemotherapy) in relapsed/refractory B-cell non-Hodgkin lymphoma was terminated, an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Magrolimab (Hu5F9-G4) (magrolimab)
• Rituximab (rituximab)

Snippet

Sponsor: Gilead Sciences | Conditions: Non Hodgkin Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-05-29